Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer

Launched by JING-KUN LIU · Apr 16, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how the bacteria in our gut, known as gut microbiota, may affect how patients with locally advanced rectal cancer respond to radiation treatment. Specifically, the study aims to identify which types of bacteria could be linked to better or worse responses to this therapy. By learning more about these changes in gut bacteria, researchers hope to develop new treatment strategies that could improve the effectiveness of radiation therapy for rectal cancer patients.

To be eligible for this trial, participants must be between 18 and 75 years old and diagnosed with late-stage rectal cancer (specifically stages IIIB to IV). They should also have measurable cancer lesions and be in good enough health to undergo radiation or chemotherapy. Importantly, patients with severe health issues, other cancers, or certain allergies will not be able to participate. If you join this study, you can expect to undergo assessments of your gut bacteria and receive treatment as part of the trial. This research is not yet recruiting participants, but it aims to pave the way for more effective cancer treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with late-stage rectal cancer (stages IIIB to IV), including those with postoperative recurrence re-staging or those intending to receive neoadjuvant treatment,
• • 2. Pathological type is adenocarcinoma,
• • 3. Have measurable lesions before radiotherapy or chemotherapy,
• • 4. Age between 18 and 75 years,
• • 5. A WHO Performance Status (PS) score of 0 to 2, capable of tolerating radiotherapy or chemotherapy,
• • 6. An expected survival period of 6 months or more;
• • 7. Able to understand the study and sign the informed consent form.
• Exclusion Criteria:
• • 1. Patients with severe complications or other malignant diseases.
• • 2. Known severe allergic reactions to components of radiotherapy or chemotherapy.
• • 3. Significant cardiac, hepatic, renal, or other vital organ dysfunction.
• • 4. Pregnant or breastfeeding women.
• • 5. Patients unable to comply with study requirements or affected by psychiatric or psychological diseases.
• • 6. Participation in other clinical trials recently that could affect the assessment of this study's results.